Tevogen Bio, a clinical-stage specialty immunotherapy company, said July 17 that it signed a letter of intent to lease a 17,428-square-foot facility in Warren. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the company’s cell-therapy manufacturing operations.
The facility aligns with Tevogen’s goals of accelerating clinical development while maintaining cost efficiency and scalability. The facility’s intended use will be for GMP (good manufacturing practice) cell-therapy manufacturing and complement Tevogen’s anticipated growing pipeline powered by PredicTcell, the company’s proprietary AI-driven target discovery platform.
The lease term is expected to be greater than five years and the company anticipates that it will begin occupancy following final lease execution and completion of necessary approvals.
“Our continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,” said Dr. Ryan Saadi, CEO of Tevogen Bio. “This facility has potential to efficiently scale our manufacturing as we advance our pipeline toward commercialization and will serve as a bridge as we enter the early stages of developing our own custom-built manufacturing facility.”
Online stock news site stocktitan.net said that “strategically, this facility serves as a transitional solution while the company plans a future custom-built manufacturing facility. This two-phase approach allows Tevogen to establish manufacturing capabilities more quickly while planning for greater scale.”
The site added that “Tevogen’s new manufacturing facility bolsters its cell- therapy pipeline by providing in-house production capabilities critical for clinical development and commercialization.”
Earlier this month, Tevogen announced a lease agreement that will double the footprint at its Warren headquarters to about 13,000 square feet. Financial terms were not disclosed.
The added space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development, which was previously located in Philadelphia. The extra space is intended to increase operational efficiency and cross-team collaboration.
